Manila Times Business
BriaCell Presents Positive Clinical Data at ASCO 2026
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 studyBiomarker analyses from the ongoing Phase 3 study further validates potential predictors of anti-cancer respons
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bonoan rushed to hospital over ‘near stroke’ — Remulla
Just now
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Just now
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Just now
Brixton Metals Drills 2.3 m of 1,811 g/t Silver within 27.7 m of 166.45 g/t Silver at its Langis Project
Just now